Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

Фаза 3 Завершено NCT04662710

Кратко

The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared with chemotherapy alone in participants with advanced/metastatic gastroesophageal cancer. The primary study hypotheses are that lenvatinib plus pembrolizumab plus chemotherapy is superior to chemotherapy alone for both overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), in participants with programmed cell death-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 and in all participants.

Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)

Up to ~21 days · Participants

Part 1: Number of Participants With Adverse Events (AEs)

Up to ~44 months · Participants

Part 1: Number of Participants Who Discontinued Study Treatment Due to an AE

Up to ~29 months · Participants

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Все исследования